drugset / Trial / NCT03769155
VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma
Phase 1
Active not recruiting
41 enrolled
Emory University
Bristol-Myers Squibb · collabNational Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collabVaccinex Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This pilot phase I trial studies how well VX15/2503 (pepinemab) with or without ipilimumab and/or nivolumab work in treating participants with stage IIIB-D melanoma that can be removed by surgery. Monoclonal antibodies, such as VX15/2503, ipilimumab, and nivolumab may interfere with the ability of tumor cells to grow and spread.
Timeline
- Start
- 2018-12-13
- Primary completion
- 2023-12-15
- Completion
- 2032-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |
| Subject | Pepinemab | Monoclonal antibody | — | Intravenous |